Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model.

Sci Rep 2019 Jan 24;9(1):530. Epub 2019 Jan 24.

Xiphophorus Genetic Stock Center, Department of Chemistry and Biochemistry, 419 Centennial Hall, Texas State University, San Marcos, TX, USA.

Cell culture and protein target-based compound screening strategies, though broadly utilized in selecting candidate compounds, often fail to eliminate candidate compounds with non-target effects and/or safety concerns until late in the drug developmental process. Phenotype screening using intact research animals is attractive because it can help identify small molecule candidate compounds that have a high probability of proceeding to clinical use. Most FDA approved, first-in-class small molecules were identified from phenotypic screening. However, phenotypic screening using rodent models is labor intensive, low-throughput, and very expensive. As a novel alternative for small molecule screening, we have been developing gene expression disease profiles, termed the Transcriptional Disease Signature (TDS), as readout of small molecule screens for therapeutic molecules. In this concept, compounds that can reverse, or otherwise affect known disease-associated gene expression patterns in whole animals may be rapidly identified for more detailed downstream direct testing of their efficacy and mode of action. To establish proof of concept for this screening strategy, we employed a transgenic strain of a small aquarium fish, medaka (Oryzias latipes), that overexpresses the malignant melanoma driver gene xmrk, a mutant egfr gene, that is driven by a pigment cell-specific mitf promoter. In this model, melanoma develops with 100% penetrance. Using the transgenic medaka malignant melanoma model, we established a screening system that employs the NanoString nCounter platform to quantify gene expression within custom sets of TDS gene targets that we had previously shown to exhibit differential transcription among xmrk-transgenic and wild-type medaka. Compound-modulated gene expression was identified using an internet-accessible custom-built data processing pipeline. The effect of a given drug on the entire TDS profile was estimated by comparing compound-modulated genes in the TDS using an activation Z-score and Kolmogorov-Smirnov statistics. TDS gene probes were designed that target common signaling pathways that include proliferation, development, toxicity, immune function, metabolism and detoxification. These pathways may be utilized to evaluate candidate compounds for potential favorable, or unfavorable, effects on melanoma-associated gene expression. Here we present the logistics of using medaka to screen compounds, as well as, the development of a user-friendly NanoString data analysis pipeline to support feasibility of this novel TDS drug-screening strategy.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-36656-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345854PMC
January 2019
5 Reads

Publication Analysis

Top Keywords

gene expression
20
candidate compounds
16
small molecule
12
gene
9
tds gene
8
malignant melanoma
8
phenotypic screening
8
disease signature
8
transcriptional disease
8
screening
7
compounds
7
tds
6
small
6
expression
5
model melanoma
4
melanoma develops
4
develops 100%
4
mutant egfr
4
xmrk mutant
4
mitf promoter
4

References

(Supplied by CrossRef)

MA Lindsay et al.
Nat Rev Drug Discov 2003

B Munos et al.
Nat Rev Drug Discov 2009

M Williams et al.
Biochem Pharmacol 2005

CS Flordellis et al.
Curr Top Med Chem 2006

DC Swinney et al.
Nat Rev Drug Discov 2011

D Kokel et al.
Nat Chem Biol 2010

RM White et al.
Nature 2011

P Gut et al.
Nat Chem Biol 2013

S Ridges et al.
Blood 2012

Similar Publications